What is CoImmune?
CoImmune operates at the forefront of the biotechnology sector, specializing in the development of next-generation cellular immunotherapies. The company distinguishes itself through two primary technological pillars: an allogeneic CAR-CIK platform designed to address both liquid and solid tumors with reduced toxicity compared to traditional CAR-T therapies, and an autologous RNA-loaded dendritic cell technology. By utilizing amplified total tumor mRNA, CoImmune programs dendritic cells to mount a robust immune response against neoantigens, effectively bypassing the need for individual neoantigen identification. This approach positions the company as a high-authority player in the oncology space, aiming to redefine treatment efficacy for patients with complex malignancies.
How much funding has CoImmune raised?
CoImmune has raised a total of $45M across 1 funding round:
Series A
$45M
Series A (2020): $45M with participation from Dr. Lucio Rovati
Key Investors in CoImmune
Dr. Lucio Rovati
A prominent investor and industry expert with a focus on supporting high-potential clinical-stage biotechnology ventures.
What's next for CoImmune?
With the infusion of this latest capital, CoImmune is expected to transition into a more aggressive phase of clinical validation and operational scaling. The strategic focus will likely center on advancing its lead candidates through rigorous human trials, optimizing manufacturing processes for its allogeneic platforms, and expanding its intellectual property portfolio. As the company moves deeper into its clinical-stage lifecycle, the focus will shift toward demonstrating long-term safety and efficacy data, which will be critical for future regulatory milestones and potential commercial partnerships. The current financial backing provides the necessary runway to navigate the high-barrier entry of the immuno-oncology market while maintaining a competitive edge in therapeutic innovation.
See full CoImmune company page
